Liquidia Technologies, Inc.

Quick facts

Phase 3 pipeline

• L606 · Pulmonary Hypertension
  L606 is an inhaled dry powder formulation of treprostinil designed to deliver the prostacyclin analog directly to the lungs for pulmonary hypertension treatment.
• LIQ861 Inhaled Treprostinil · Cardiovascular / Pulmonary Hypertension
  LIQ861 is an inhaled formulation of treprostinil, a prostacyclin analog that vasodilates pulmonary and systemic blood vessels by activating prostacyclin receptors.

Phase 2 pipeline

• LIQ861

Phase 1 pipeline

• Diluent for LIQ865
• LIQ865A bupivacaine formulation
• LIQ865B bupivacaine formulation

Competitive intelligence

For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:

• Liquidia Technologies, Inc. portfolio CI brief
• Liquidia Technologies, Inc. pipeline updates RSS